Cytokinetics (CYTK) Announces Proposed $150M Share Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Cytokinetics (CYTK) Prices 7.29M Share Common Offering at $24/Sh
July 17, 2020 5:56 AM EDTCytokinetics, Incorporated (NASDAQ: CYTK) today announced the pricing of an underwritten public offering of 7,291,667 shares of its common stock at a price to the public of $24.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting... More
Cytokinetics (CYTK) PT Raised to $29 at JMP Securities
July 15, 2020 4:17 AM EDTJMP Securities raised its price target on Cytokinetics (NASDAQ: CYTK) to $29.00 (from $23.00) while maintaining a Market Outperform rating.... More
Cytokinetics (CYTK) PT Raised to $38 at H.C. Wainwright, After Licensing Collaboration Announced
July 14, 2020 12:12 PM EDTH.C. Wainwright analyst Joseph Pantginis raised the price target on Cytokinetics (NASDAQ: CYTK) to $38.00 (from $35.00) while maintaining a Buy rating.
... MoreCytokinetics (CYTK) PT Raised to $33 at Piper Sandler, After Licensing Collaboration Announced
July 14, 2020 11:11 AM EDTPiper Sandler analyst Edward A. Tenthoff raised the price target on Cytokinetics (NASDAQ: CYTK) to $33.00 (from $28.00) while maintaining a Overweight rating.
... MoreCytokinetics (CYTK) Reports Licensing Collaboration & Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor
July 14, 2020 7:32 AM EDTCytokinetics, Incorporated (NASDAQ: CYTK) today announced that it has agreed to a series of transactions with certain companies wholly owned by investment funds managed by RTW Investments, LP, and Ji Xing Pharmaceuticals Limited (Ji Xing), related to CK-3773274 (CK-274), a next-generation cardiac myosin inhibitor that Cytokinetics is developing for the potential treatment of hypertrophic cardiomyopathies (HCMs) and other clinical indications that may be associated with excessive cardiac muscle contractility. Pursuant to these transactions, Cytokinetics will receive a combination of committed capital, funding and sale proceeds of up to $250 million from RTW and is eligible to... More
